Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid Tumors

Trial Profile

A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Nov 2018

At a glance

  • Drugs Atezolizumab (Primary) ; PRS 343 (Primary)
  • Indications Bladder cancer; Breast cancer; Gastric cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Pieris Pharmaceuticals
  • Most Recent Events

    • 07 Nov 2018 According to a Pieris Pharmaceuticals media release, Company intends to report data from this trial in 2019.
    • 04 Sep 2018 According to a Pieris Pharmaceuticals media release, first patient has been dosed in the trial. The company expects to report findings from the study next year.
    • 27 Aug 2018 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top